Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program

Pediatrics

Volumn 127, Issue SUPPL. 1, 2011, Pages

  Salmon, Daniel A ^a   Akhtar, Aysha ^b   Mergler, Michelle J ^a   Vannice, Kirsten S ^a   Izurieta, Hector ^b   Ball, Robert ^b   Lee, Grace M ^c   Vellozzi, Claudia ^d   Garman, Patrick ^e   Cunningham, Francesca ^f   Gellin, Bruce ^a   Koh, Howard ^a   Lurie, Nicole ^a   Burwen, Dale R ^g   Butler, Jay C ^g   Caserta, Vito ^g   Curlin, George ^g   DeStefano, Frank ^g   Elliot, Arthur ^g   Groom, Amy V ^g   Hughes, Hayley ^g   Helfand, Rita ^g   Hua, Wei ^g   Kelman, Jeffrey ^g   Korch, George ^g   Krause, Philip R ^g   Landry, Sarah ^g   Midthun, Karen ^g   Qiang, Yandong ^g   Redd, John T ^g   Skillen, Elizabeth L ^g   Sutherland, Andrea R ^g   Weinbaum, Cindy ^g   Wise, Robert P ^g   more..

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^e Military Vaccine Agency   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

^g Department of Veterans Affairs ^*

Author keywords

H1N1 influenza; Vaccine safety

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADVERSE DRUG REACTION; CASE FINDING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GUILLAIN BARRE SYNDROME; INFLUENZA VACCINATION; INFORMATION PROCESSING; INFORMATION SYSTEM; MEDICAL INFORMATION SYSTEM; MEDICARE; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; UNITED STATES;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CHILD; DISEASE OUTBREAKS; DRUG TOXICITY; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROGRAM EVALUATION; SAFETY MANAGEMENT; UNITED STATES; YOUNG ADULT;

EID: 79955486652     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-1722L     Document Type: Review

References (28)

1. Black S, Eskola J, Siegrist CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009;374(9707):2115-2122
2. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965; 58:295-300
3. Inter-Agency Vaccine Group, Department of Defense and Veterans Affairs. A comprehensive review of federal vaccine safety activities. Available at: www.hhs.gov/nvpo/nvac/documents/vaccine-safety-review.pdf. Accessed March 10, 2010
4. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine: United States, 1998-1999. MMWR Morb Mortal Wkly Rep. 1999;48(27):577-581
5. Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J. 2004;23(4):287-294 (Pubitemid 38508877)
6. Rubertone MV, Brundage JF. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health. 2002;92(12):1900-1904 (Pubitemid 35386611)
7. McNeil MM, Ma G, Aranas A, Payne DC, Rose CE. A comparative assessment of immunization records in the Defense Medical Surveillance System and the Vaccine Adverse Event Reporting System. Vaccine. 2007;25(17):3428-3436 (Pubitemid 46546450)
8. Grabenstein JD, Winkenwerder W. US military smallpox vaccination program experience. JAMA. 2003;289(24):3278-3282 (Pubitemid 37430081)
9. Ball R, Shadomy SV, Meyer A, et al. HLA type and immune response to Borrelia burgdorferi outer surface protein A in people in whom arthritis developed after Lyme disease vaccination. Arthritis Rheum. 2009;60(4):1179-1186
10. National Vaccine Advisory Committee. Recommendations on 2009 H1N1 influenza vaccine safety monitoring: approved by the National Vaccine Advisory Committee on July 27, 2009. Available at: www.hhs.gov/nvpo/nvac/meetings/ pastmeetings/h1n1subgrouprecommendationsvsmjuly2009.html. Accessed February 11, 2010
11. National Vaccine Advisory Committee. 2009 H1N1 influenza vaccine safety monitoring recommendation. Available at: www.hhs.gov/nvpo/nvac/meetings/ pastmeetings/h1n1vaccinesafetymonitoringrecs.doc. Accessed February 11, 2010
12. Olmsted SS, Grabenstein JD, Jain AK, et al. Use of an electronic monitoring system for self-reporting smallpox vaccine reactions. Biosecur Bioterror. 2005;3(3):198-206 (Pubitemid 43978719)
13. Olmsted SS, Grabenstein JD, Jain AK, Lurie N. Patient experience with, and use of, an electronic monitoring system to assess vaccination responses. Health Expect. 2006;9(2):110-117 (Pubitemid 43742678)
14. Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009;27(15):2114-2120
15. Nakamura N, Nokura K, Zettsu T, et al. Neurologic complications associated with influenza vaccination: two adult cases. Intern Med. 2003;42(2):191-194 (Pubitemid 36372361)
16. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine [published correction appears in JAMA. 2005;294(24):3092]. JAMA. 2005;294(21):2720-2725 (Pubitemid 41770101)
17. Vasu N, Ghaffari G, Craig ET, Craig TJ. Adverse events associated with intranasal influenza vaccine in the United States. Ther Adv Respir Dis. 2008;2(4):193-198
18. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005;23(30):3876-3886 (Pubitemid 40726180)
19. Huynh W, Cordato DJ, Kehdi E, Masters LT, Dedousis C. Post-vaccination encephalomyelitis: literature review and illustrative case. J Clin Neurosci. 2008;15(12):1315-1322
20. Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine. 2007;25(3):570-576
21. Larner AJ, Farmer SF. Myelopathy following influenza vaccination in inflammatory CNS disorder treated with chronic immunosuppression. Eur J Neurol. 2000;7(6):731-733 (Pubitemid 32154410)
22. Bakshi R, Mazziotta JC. Acute transverse myelitis after influenza vaccination: Magnetic resonance imaging findings. J Neuroimaging. 1996;6(4):248-250 (Pubitemid 26371234)
23. Kavadas FD, Bitnun A, Macgregor D, Heurter H, Jones ELF. Acute neurological events associated with influenza vaccination: are the WHO criteria for assessing causality adequate? Scand J Infect Dis. 2008;40(6-7):565-570 (Pubitemid 351997679)
24. Poser CM. Neurological complications of swine influenza vaccination. Acta Neurol Scand. 1982;66(4):413-431 (Pubitemid 12033260)
25. Velentgas P, Bohn RL, Brown JS, et al. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. Pharmacoepidemiol Drug Saf. 2008;17(12):1226-1234
26. Centers for Medicare and Medicaid Services. CMS manual system: transmittal 1810 - October update to the 2009 Medicare Physician Fee Schedule Database (MPFSDB). Available at: www.cms.gov/transmittals/downloads/R1810CP.pdf. Accessed January 3, 2011
27. Centers for Medicare and Medicaid Services. CMS manual system: transmittal 1803 - update of the Hospital Outpatient Prospective Payment System (OPPS). Available at: www.cms.gov/transmittals/downloads/R1803CP.pdf. Accessed January 3, 2011
28. National Vaccine Advisory Committee. Report on 2009 H1N1 vaccine safety risk assessment. Available at: www.hhs.gov/nvpo/nvac/reports/ 2010vaccinesafetyreport.html. Accessed on February 11, 2010